These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21576997)

  • 1. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
    Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
    Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
    Jamar F; Fiasse R; Leners N; Pauwels S
    J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
    Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
    J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma.
    Leners N; Jamar F; Fiasse R; Ferrant A; Pauwels S
    J Nucl Med; 1996 Jun; 37(6):916-22. PubMed ID: 8683311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
    Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
    Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
    Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
    Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
    Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
    J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
    Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
    J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system].
    Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO
    Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
    Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
    Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
    Pauwels S; Leners N; Fiasse R; Jamar F
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
    [No Abstract]   [Full Text] [Related]  

  • 15. Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors.
    Bombardieri E; Seregni E; Savelli G; Villano C; Castellani MR; Cirillo F; Pallotti F; Fracassi S; Chiesa C; Chiti A; Bajetta E
    J Endocrinol Invest; 2003; 26(8 Suppl):63-9. PubMed ID: 15233216
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of (111)In-DTPA-pentetreotide scintigraphy in accurate diagnosis of neuroendocrine gastroenteropancreatic tumors.
    Ichijo T; Ishikawa M; Shimojo M; Tsubuku M; Tsuboi K; Miyachi Y
    J Hepatobiliary Pancreat Surg; 2001; 8(5):473-8. PubMed ID: 11702259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a Correction Method for
    Kanzaki T; Takahashi Y; Higuchi T; Zhang X; Mogi N; Suto T; Tsushima Y
    J Nucl Med Technol; 2020 Dec; 48(4):326-330. PubMed ID: 32887762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.
    McCarthy KE; Woltering EA; Espenan GD; Cronin M; Maloney TJ; Anthony LB
    Cancer J Sci Am; 1998; 4(2):94-102. PubMed ID: 9532411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors.
    Nauck C; Ivancević V; Emrich D; Creutzfeldt W
    Z Gastroenterol; 1994 Jun; 32(6):323-7. PubMed ID: 7975760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraoperative gamma probe detection of neuroendocrine tumors.
    Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
    J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.